Condition: High Cholesterol · Sponsor: Ikaria Bioscience Pty Ltd
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of single doses of RN5681 in Adult healthy subjects
This description comes directly from the study's public registry record.
Dan Xiang · +86 18516063568 · dan.xiang@ronatherapeutics.com
Jie Zeng · jie.zeng@ronatherapeutics.com · jie.zeng@ronatherapeutics.com
Always discuss trial participation with your own doctor first.
| Q-Pharm Pty Ltd. | Brisbane, Queensland, Australia | Recruiting |
| Nucleus Network Pty Ltd. | Melbourne, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07347678